Related Experiment Video
Updated: May 3, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Antitumor efficacy of argon-helium cryoablation-generated dendritic cell vaccine in glioma
Zhilin Yin1, Guohui Lu, Zhenyong Xiao
1aDepartment of Neurosurgery, Zhujiang Hospital bThe National Key Clinic Specialty, Key Laboratory on Brain Function Repair and Regeneration, The Neurosurgery Institute of Guangdong Province, Southern Medical University, Guangzhou, China.
Abstract:
Dendritic cells (DCs) are potent antigen-presenting cells that play a critical role in priming tumor immune responses. We investigated the mechanisms of antitumor efficacy of DCs pulsed with argon-helium-cryotreated glioma cells. There was significant upregulation of maturation markers (CD80, CD86, MHC-I, and MHC-II) in argon-helium freeze-thawed lysate-pulsed DCs. The concentration of interleukin-6 (IL-6), IL-1β, tumor necrosis factor-α, and IL-12 secreted by lysate-pulsed DCs was increased. The concentration of interferon-γ secreted by T cells stimulated by lysate-pulsed DCs was increased. The cytotoxicity assay showed that T cells stimulated by lysate-pulsed DCs could kill glioma cells significantly more effectively. Our results suggest that argon-helium freeze-thawed lysate-pulsed DCs in vitro can promote DC maturation and enhance DC antigen-presenting function, and induce cytotoxic T lymphocytes to kill tumor cells. Therefore, the combination of argon-helium cryoablation and DC vaccine may represent a novel treatment method for glioma.

